Since, in the current study, depression is the disease state related to the greatest number of PGx gene–drug pairs having both FDA/CPIC categorizations, it is worth highlighting that CYP2C19 and CYP2D6 are primarily responsible for the metabolism of those antidepressant medications. The gene discussed is CYP2D6; the disease is depressive disorder.